MA22889A1 - Procede de preparation de produits nouveaux - Google Patents

Procede de preparation de produits nouveaux

Info

Publication number
MA22889A1
MA22889A1 MA23182A MA23182A MA22889A1 MA 22889 A1 MA22889 A1 MA 22889A1 MA 23182 A MA23182 A MA 23182A MA 23182 A MA23182 A MA 23182A MA 22889 A1 MA22889 A1 MA 22889A1
Authority
MA
Morocco
Prior art keywords
preparation
new products
products
new
Prior art date
Application number
MA23182A
Other languages
English (en)
Inventor
Derrick Gribble Andrew
Ellwood Dolle Roland
Nicholas Shaw Antony
Hendrik Evert Groot Pieter
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA22889A1 publication Critical patent/MA22889A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA23182A 1992-05-05 1993-05-03 Procede de preparation de produits nouveaux MA22889A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209628A GB9209628D0 (en) 1992-05-05 1992-05-05 Compounds

Publications (1)

Publication Number Publication Date
MA22889A1 true MA22889A1 (fr) 1993-12-31

Family

ID=10714988

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23182A MA22889A1 (fr) 1992-05-05 1993-05-03 Procede de preparation de produits nouveaux

Country Status (10)

Country Link
US (1) US5447954A (fr)
EP (1) EP0639187A1 (fr)
JP (1) JPH08500085A (fr)
CN (1) CN1092418A (fr)
AU (1) AU4041293A (fr)
GB (1) GB9209628D0 (fr)
IL (1) IL105586A0 (fr)
MA (1) MA22889A1 (fr)
SI (1) SI9300238A (fr)
WO (1) WO1993022304A1 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303144T1 (de) * 1995-11-17 2005-09-15 Univ Johns Hopkins Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge
DE19705718A1 (de) * 1997-02-14 1998-08-20 Horst P O Dr Wolf Neue Oxirancarbonsäuren zur Behandlung des Diabetes Typ 2 und anderer insulinresistenter Zustände
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP4598917B2 (ja) * 2000-04-28 2010-12-15 ダイセル化学工業株式会社 ラクトンの製造方法
EP1332139B1 (fr) 2000-10-23 2007-04-04 Arizona Biomedical Research Commission Agents anticancereux dont l'action repose sur la regulation de la prenylation de proteines
WO2003002732A1 (fr) * 2001-06-27 2003-01-09 Biovitrum Ab Polypeptides de citrate lyase
AU2002348276A1 (en) * 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
EP1504525A2 (fr) * 2002-05-14 2005-02-09 Siemens Aktiengesellschaft Procede pour generer un signal d'emission
KR100983990B1 (ko) * 2002-05-28 2010-09-30 아지노모토 가부시키가이샤 Ａｔｐ 시트르산 리아제의 발현 억제용 의약 조성물
EP1626711A4 (fr) * 2003-05-09 2010-10-06 Univ Pennsylvania Compositions et methodes de traitement anticancereux
DE20312620U1 (de) * 2003-08-14 2003-10-09 Bsh Bosch Siemens Hausgeraete Kältegerät mit Türsicherung
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
KR100918322B1 (ko) * 2003-11-12 2009-09-22 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1778220A1 (fr) * 2004-07-12 2007-05-02 Phenomix Corporation Composes cyano contraints
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076597A1 (fr) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques constituant des modulateurs des recepteurs cannabinoides
US7314882B2 (en) * 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques servant de modulateurs au recepteur de cannabinoides
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
ES2319461T3 (es) * 2005-02-10 2009-05-07 Bristol-Myers Squibb Company Dihidroquinazolinonas como moduladores de 5ht.
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7572808B2 (en) * 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
CA2617102A1 (fr) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Tetrahydro-1h-pyrido[4,3,b]indoles substitues utilises en tant qu'agonistes et antagonistes des recepteurs de la serotonine
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008057856A2 (fr) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATEURS DU RÉCEPTEUR DES GLUCOCORTICOÏDES ET DE L'ACTIVITÉ DE AP-1 ET / OU DE NF-ϰB ET UTILISATION DESDITS MODULATEURS
EP2089389A2 (fr) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Modulateur du récepteur de glucocorticoïdes, ap-1, et/ou activité de nf-kb et leur utilisation
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
EP2089355A2 (fr) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulateurs de recepteur de glucocorticoide, d'activite ap-1 et/ou nf- kappa b, et leur utilisation
EP2581081A3 (fr) 2007-06-01 2013-07-31 The Trustees Of Princeton University Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
ES2448839T3 (es) 2007-11-01 2014-03-17 Bristol-Myers Squibb Company Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010104818A1 (fr) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Analogues d'azapyridone utiles comme antagonistes du récepteur 1 de l'hormone concentrant la mélanine
WO2010104830A1 (fr) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Analogues de pyridone utiles comme antagonistes du récepteur 1 de l'hormone concentrant la mélanine
CA2756786A1 (fr) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Procedes destines a prevenir des evenements cardiovasculaires indesirables majeurs par des inhibiteurs de la dpp-iv
US9346852B2 (en) 2011-03-14 2016-05-24 Bristol-Myers Scuibb Company Substituted adipic acid amides and uses thereof
US8815909B2 (en) 2011-07-18 2014-08-26 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
US8710049B2 (en) 2011-07-18 2014-04-29 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
EP2892897A1 (fr) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Antagonistes du récepteur 1 d'hormone concentrant la mélanine de type pyrrolone ou pyrrolidinone
WO2014039411A1 (fr) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Antagonistes du récepteur 1 de l'hormone de concentration de pyrrolone ou pyrrolidinone mélanine
WO2015027021A1 (fr) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Dérivés imide et acylurée utilisés comme modulateurs du récepteur de glucocorticoïdes
WO2015049365A2 (fr) 2013-10-03 2015-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques permettant la modulation de l'autophagie chez un sujet ayant besoin d'un tel traitement
WO2016207867A1 (fr) 2015-02-25 2016-12-29 Université Du Luxembourg Nat8l et n-acétylaspartate dans le cancer
JP2021517589A (ja) 2018-03-12 2021-07-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE478147C (de) * 1926-03-19 1929-06-19 Hermann Wintzer Metallgiessere Vorrichtung zum Antrieb von Schmierkolbenpumpen
US3248187A (en) * 1961-12-22 1966-04-26 Exxon Research Engineering Co Alkenyl dicarboxylic acid lactones, their method of preparation and utility
GB1037985A (en) * 1963-02-19 1966-08-03 Cheuron Res Company Alkylbutyrolactone-ª‡-acetic acids
DE3813806A1 (de) * 1988-04-23 1989-11-02 Basf Ag 11-hydroxy-(gamma)-dodecalacton und seine herstellung
JP2796884B2 (ja) * 1990-08-30 1998-09-10 高砂香料工業株式会社 光学活性γ―ブチロラクトン誘導体の製造方法

Also Published As

Publication number Publication date
US5447954A (en) 1995-09-05
IL105586A0 (en) 1993-12-28
JPH08500085A (ja) 1996-01-09
AU4041293A (en) 1993-11-29
CN1092418A (zh) 1994-09-21
GB9209628D0 (en) 1992-06-17
WO1993022304A1 (fr) 1993-11-11
SI9300238A (sl) 1993-12-31
EP0639187A1 (fr) 1995-02-22

Similar Documents

Publication Publication Date Title
MA22889A1 (fr) Procede de preparation de produits nouveaux
MA23528A1 (fr) Procede de preparation de produits pharmaceutiques
MA22923A1 (fr) Procede de preparation de nouveaux composes .
MA22922A1 (fr) Procede pour la preparation de nouveaux composes .
MA23850A1 (fr) Procede de preparation de compositions vaccinantes
MA23918A1 (fr) Procede de preparation de compositions vaccinantes
MA23814A1 (fr) Procede de preparation de compositions vaccinantes
MA23254A1 (fr) Procede de preparation de nouveaux composes
FR2608900B1 (fr) Procede de fabrication de produits de charcuterie
FR2629471B1 (fr) Procede de preparation de demi-produits en cuir
MA22955A1 (fr) Procede pour la preparation de nouveaux composes .
MA23518A1 (fr) Procede de preparation de produits pharmaceutiques
EP0569331A3 (en) Process for the preparation of addition products
MA21348A1 (fr) Procede pour la preparation de nouveaux derives aminoalcoxyphenyle.
PT87503A (pt) Process for the preparation of new cathecolamine by products
PT87309A (pt) Process for the preparation of benzazepine by products
MA22848A1 (fr) Procede enzymatique pour la preparation des aryl-piperidines
ITMI920134A0 (it) Procedimento migliorato per la produzione di calcourea
FI944507A0 (fi) Menetelmä oksotuotteiden valmistamiseksi
FR2655340B1 (fr) Procede de preparation de produits intermediaires pour la preparation de diltiazem.
MA22880A1 (fr) Procede de preparation de produits pharmaceutiques .
NO179244C (no) Fremgangsmåte for kontinuerlig fremstilling av dimetoksyetanal
HU902047D0 (en) Process for the preparation of pharmaceutical product
MC2243A1 (fr) Procede de preparation de dimeres de la ribonuclease
MA22927A1 (fr) Procede pour la preparation de nouveaux composes.